A Prospective, Open Label, Dual Cohort Study of Cadonilimab（AK104）Combined With Standard Treatment for Function Preservation in Urinary System Tumors
Trial Snapshot
- Phase
- Phase 2
- Status
- Not yet recruiting
- Sponsor
- Tongji Hospital
- Enrollment
- 40
- Primary Endpoint
- Bladder/Kidney Preservation rate
Study Overview
Brief Summary
This is an open label, dual cohort ,phase II study to explore efficacy and safety of cadonilimab(PD-1/CTLA-4 Bispecific Antibody) combined with standard regimen neoadjuvant treatment in urothelial carcinoma（UC） and renal cell carcinoma（RCC）, with evaluating successful preservation rate of bladder/kidney.
Detailed Description
UC and RCC confirmed by histopathology or cytology prior have not received systematic treatment, who had indications for surgical resection and were difficult to preserve organ function after surgery or were partially resection but the patients have a strong desire to preserve organ function. This study enrolled 20 cases in each cohort of UC and RCC，pts received neoadjuvant treatment containing cadonilimab for no more than 6 cycles.
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Voluntary agreement to provide written informed consent.
- •Male or female, Age ≥ 18 years.
- •Predicted survival ≥ 12 weeks.
- •Histologically confirmed diagnosis of urothelial carcinoma（UC） and renal cell carcinoma（RCC）.
- •Prior no antitumor systematic treatment .
- •Have clinically non-metastatic high risk urothelial carcinoma (cT2-T4a, N0-3, M0) .
- •High risk renal cell carcinoma (≥ T2Nx or TanyN+)，include subjects with only Oligotransfer.
- •Willing to undergo surgical resection and were difficult to preserve organ function after surgery or were partially resection but the patients have a strong desire to preserve organ function.
- •Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or
- •Adequate organ function, evidenced by the following laboratory results within 7 days prior to the study treatment.
- •Male and female participants are eligible to participate if they agree to the contraception use as per study protocol.
- •Willing to adhere to the study visit schedule and the prohibitions and restrictions specified in this protocol.
Exclusion Criteria
- •Has received other antitumor therapy before planned start of trial treatment.
- •History of major surgery within 4 weeks of planned start of trial treatment.
- •Diagnosed with HBsAg, HBcAb positive and HBV DNA copy positive, or HCVAb positive, or HIVAb positive.
- •Has received a live virus vaccine within 4 weeks of planned start of trial treatment.
- •NYHA Class III heart failure.
- •Suffering from active infection requiring systemic treatment.
- •Uncontrolled hypertension, diabetes, Interstitial lung Disease, or COPD;
- •Treated with systemic treatment (e.g. immunomodulators, corticosteroids or immunosuppressants) for the autoimmune disease within 2 years prior to the study treatment.
- •History of other malignancy within the previous 5 years, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or cancers with a similar curative outcome as those mentioned above.
- •Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.
- •Pregnancy or lactation.
- •Assessed by the investigator to be unable or unwilling to comply with the requirements of the protocol.
Arms & Interventions
UC
Patients will receive AK104 (10mg/kg ,Q3W，intravenously) plus standard regimen （gemcitabine or albumin paclitaxel) neoadjuvant treatment with no more than 6 cycles.
Intervention: Cadonilimab plus chemotherapy (Drug)
RCC
Patients will receive AK104 (10mg/kg ,Q3W，intravenously) plus standard regimen （TKI，e.g. sunitinib, pezopanib) neoadjuvant treatment with no more than 6 cycles.
Intervention: Cadonilimab plus TKI (Drug)
Outcomes
Primary Outcomes
Bladder/Kidney Preservation rate
Time Frame: Up to approximately 18 Weeks (Time of surgery)
Evaluating the impact of neoadjuvant therapy on organ preservation function
Secondary Outcomes
- Overall Survival (OS)(Up to approximately 36 Months)
- Rate of Pathologic Response(Up to approximately 18 Weeks (Time of surgery) ])
- Objective Response Rate (ORR)(Up to approximately 18 Weeks)
- Assess Adverse Events(12 months)
Investigators
Liu Huang
Clinical Professor
Tongji Hospital